Search

Your search keyword '"Gregucci, F."' showing total 177 results
Start Over Author "Gregucci, F."
177 results on '"Gregucci, F."'

1. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma

Author

Caccese, M., Desideri, I., Villani, V., Simonelli, M., Buglione, M., Chiesa, S., Franceschi, E., Gaviani, P., Stasi, I., Caserta, C., Brugnara, S., Lolli, I., Bennicelli, E., Bini, P., Cuccu, A.S., Scoccianti, S., Padovan, M., Gori, S., Bonetti, A., Giordano, P., Pellerino, A., Gregucci, F., Riva, N., Cinieri, S., Internò, V., Santoni, M., Pernice, G., Dealis, C., Stievano, L., Paiar, F., Magni, G., De Salvo, G.L., Zagonel, V., and Lombardi, G.

Published
2024
Full Text
View/download PDF

4. STEREOTACTIC ARRHYTHMIA RADIOABLATION OF PAROXYSMAL ATRIAL FIBRILLATION –STATE OF ART AND FUTURE DIRECTION

Author

Bonaparte, I., primary, Gregucci, F., additional, Dimonaco, A., additional, Surgo, A., additional, Ludovico, E., additional, Carbonara, R., additional, Paulicelli, E., additional, Sanfrancesco, G., additional, Depascali, C., additional, Ciliberti, M.P., additional, Calbi, R., additional, Grimaldi, M., additional, and Fiorentino, A., additional

Published
2023
Full Text
View/download PDF

8. PO-1611 Paroxysmal atrial fibrillation in elderly: linac-based sbrt arrhythmia radioablation phase 2 trial

Author

Gregucci, F., primary, Di Monaco, A., additional, Bonaparte, I., additional, Surgo, A., additional, Carbonara, R., additional, Ciliberti, M.P., additional, Di Guglielmo, F., additional, Caliandro, M., additional, Paulicelli, E., additional, Ludovico, E., additional, Romanazzi, I., additional, Grimaldi, M., additional, and Fiorentino, A., additional

Published
2023
Full Text
View/download PDF

9. PO-2283 Analysis of target motion in STereotactic Arrhythmia Radioablation for atrial fibrillation

Author

Di Guglielmo, F.C., primary, Sanfrancesco, G., additional, De Pascali, C., additional, Gregucci, F., additional, Surgo, A., additional, Carbonara, R., additional, Ciliberti, M.P., additional, Caliandro, M., additional, Paulicelli, E., additional, Romanazzo, I., additional, Di Monaco, A., additional, Grimaldi, M., additional, Bonaparte, I., additional, and Fiorentino, A., additional

Published
2023
Full Text
View/download PDF

13. Dosimetric and Clinical Data from Linac-Based Stereotactic Arrhythmia Radioablation.

Author

Gregucci, F., Ng, J., Knisely, J.P.S., Cheung, J.W., Thomas, G., Liu, C.F., Muller, L., Pennell, R., and Formenti, S.C.

Subjects
*VOLUMETRIC-modulated arc therapy, *CARDIAC patients, *VENTRICULAR tachycardia, *CATHETER ablation, *ADVERSE health care events, *BODY surface mapping, *ARTIFICIAL implants
Abstract

Ventricular tachycardia (VT) in patients with structural heart disease is associated with reduced quality of life and poor prognosis. Therapeutic options include medication, anti-tachycardia pacing or shock by implantable cardiac devices and catheter-based ablation of heart arrhythmogenic substrates. STereotactic Arrhythmia Radioablation (STAR) tested in a phase I/II trial by Robinson and colleagues offers a novel approach. Data from a retrospective series of 5 high-risk patients with VT refractory to catheter ablation and medication, treated with STAR are reported from a single referral center. CTV was defined to encompass the arrhythmogenic substrate by a team of a radiation oncologists and treating electrophysiologists, based on clinical and electro-anatomical information derived from CT scan and catheter ablation maps. ITV was added to CTV to compensate for heart and respiratory movement. PTV was then defined by adding an isotropic margin of 2-3 mm to the ITV. Volumetric Modulated Arc Therapy (VMAT) plans were generated, optimized, and delivered using medical linear accelerator. The prescription dose to the PTV was 25 Gy in 1 fraction. Mean CTV, ITV and PTV volumes, were 141.1cc, 187.7cc, 298.1cc, respectively. Mean heart volume was 1740.6 cc. All 5 patients completed STAR procedure and treatment. There were no acute treatment-related adverse events. Clinical and treatment-efficacy data are summarized in Table. STAR significantly reduced or abrogated arrythmia at a median time of 24 weeks (range = 4-48) post-treatment. Patient n.1 and n.3 showed a remarkable reduction of VT episodes at 4- and 8-weeks post-treatment, respectively. Patients n.2, n.4 and n.5 were free of VT episodes at 6-months post-treatment. At a median follow-up time of 11 months (range = 1-19), 2/5 patients are alive (patient n.2 and n.4), both free of VT events at 1-year post-treatment. Patient n.1 died due to complication after cardiac transplantation, patients n.3 due to sepsis and multiorgan failure and patient n.5 due to COVID pneumonia, at 11-, 1- and 5-months post-STAR, respectively. These data suggest that LINAC-based STAR is a safe and effective treatment option in high-risk patients with VT refractory to catheter ablation and medication. Results from large perspective studies will define optimal patient selection and inform about long-term outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Paroxysmal Atrial Fibrillation in Elderly: Worldwide Preliminary Data of Linac-Based Stereotactic Arrhythmia Radioablation Prospective Phase II Trial

Author

Gregucci, F., primary, Di Monaco, A., additional, Bonaparte, I., additional, Surgo, A., additional, Troisi, F., additional, Ludovico, E., additional, Vitulano, N., additional, Quadrini, F., additional, Carbonara, R., additional, Ciliberti, M.P., additional, Grimaldi, M., additional, and Fiorentino, A., additional

Published
2022
Full Text
View/download PDF

15. Linac-based stereotactic arrhythmia radioablation of paroxysmal atrial fibrillation in elderly patients

Author

Di Monaco, A, primary, Gregucci, F, additional, Bonaparte, I, additional, Troisi, F, additional, Surgo, A, additional, Di Molfetta, D, additional, Vitulano, N, additional, Romanazzi, I, additional, Quadrini, F, additional, Carbonara, R, additional, Ludovico, E, additional, Guida, P, additional, Ciliberti, M P, additional, Fiorentino, A, additional, and Grimaldi, M, additional

Published
2022
Full Text
View/download PDF

18. Rethinking breast cancer follow-up based on individual risk and recurrence management

Author

De Rose, F, Meduri, B, De Santis, M, Ferro, A, Marino, L, Colciago, R, Gregucci, F, Vanoni, V, Apolone, G, Di Cosimo, S, Delaloge, S, Cortes, J, Curigliano, G, De Rose, Fiorenza, Meduri, Bruno, De Santis, Maria Carmen, Ferro, Antonella, Marino, Lorenza, Colciago, Riccardo Ray, Gregucci, Fabiana, Vanoni, Valentina, Apolone, Giovanni, Di Cosimo, Serena, Delaloge, Suzette, Cortes, Javier, Curigliano, Giuseppe, De Rose, F, Meduri, B, De Santis, M, Ferro, A, Marino, L, Colciago, R, Gregucci, F, Vanoni, V, Apolone, G, Di Cosimo, S, Delaloge, S, Cortes, J, Curigliano, G, De Rose, Fiorenza, Meduri, Bruno, De Santis, Maria Carmen, Ferro, Antonella, Marino, Lorenza, Colciago, Riccardo Ray, Gregucci, Fabiana, Vanoni, Valentina, Apolone, Giovanni, Di Cosimo, Serena, Delaloge, Suzette, Cortes, Javier, and Curigliano, Giuseppe

Abstract

Current follow-up policies for early breast cancer aim to detect loco-regional recurrences and manage treatment-related adverse effects. Their "one size fits all" approach does not take into account differences in subtypes at initial diagnosis, individual prognosis and treatments received. They are derived from clinical trials conducted when early detection means - other than mammography - and treatment options were limited. Herein, we address the arguments for re-evaluating current breast cancer follow-up strategies starting from recent advances in breast cancer local and systemic treatments and discussing individual risk of recurrence prediction models, time-adapted imaging and biomarker assessment for disease diagnostic anticipation. This change in perspective would transform breast cancer follow-up into an integrated, multidisciplinary team medical practice. Hence we discuss the important role of patient-centered approaches, but also of general practitioners and other health professionals, in the final promotion of personalized surveillance programs and patient education.

Published
2022

19. PO-1845 Surface guided adjuvant radiotherapy tattoo-free for breast cancer

Author

Cuscito, R., primary, Fragnoli, F., additional, Indelicati, C., additional, Sanfrancesco, G., additional, De Pascali, C., additional, De Masi, M., additional, Parabita, R., additional, Aga, A., additional, Berloco, F., additional, Brana', L., additional, Ciocia, A., additional, Curci, D., additional, Ladisa, G., additional, Nardiello, M., additional, Nardelli, D., additional, De Candia, V., additional, Gregucci, F., additional, Surgo, A., additional, Carbonara, R., additional, Cliliberti, M.P., additional, Caliandro, M., additional, Bonaparte, I., additional, and Fiorentino, A., additional

Published
2022
Full Text
View/download PDF

20. PO-1055 Atrial fibrillation: worldwide preliminary data of LINAC-based STAR prospective phase II trial

Author

Gregucci, F., primary, Di Monaco, A., additional, Bonaparte, I., additional, Surgo, A., additional, Troisi, F., additional, Vitulano, N., additional, Quadrini, F., additional, Di Molfetta, D., additional, Martinelli, G., additional, Guida, P., additional, Carbonara, R., additional, Ciliberti, M.P., additional, Grimaldi, M., additional, and Fiorentino, A., additional

Published
2022
Full Text
View/download PDF

23. Present clinical practice of breast cancer radiotherapy in Italy: a nationwide survey by the Italian Society of Radiotherapy and Clinical Oncology (AIRO) Breast Group

Author

Gregucci, F., Fozza, A., Falivene, S., Smaniotto, D., Morra, A., Daidone, A., Barbara, R., Ciabattoni, A., Andrulli, D., Arcidiacono, F., Baiocchi, C., Baldissera, A., Barbarino, R., Bartoncini, S., Bono, M., Buffoli, A., Campanella, B., Campoccia, S., Catalano, G., Cavallari, M., Cerreta, V., Deantonio, L., De Rose, F., Del Bufalo, S., Digennaro, D., Doino, D., Evangelista, G., Fedele, F., Fiorentino, A., Fodor, A., Fontana, A., Fusco, V., Gatti, M., Gerardi, M., Giannini, M., Girlando, A., Guenzi, M., Guida, C., Huscher, A., Iannone, T., Iorio, V., Ippolito, E., Ivaldi, G., La Porta, M., Lazzari, G., Lioce, M., Lora, O., Macchia, G., Mangiacotti, M. G., Marafioti, L., Marino, L., Marmiroli, L., Maucieri, A., Maurizi, F., Mazzuoli, L., Meattini, I., Meduri, B., Montesi, G., Munoz, F., Nuzzo, M., Orru, S., Parisi, S., Pasinetti, N., Pedretti, S., Perrucci, E., Piva, D., Prisco, A., Ravo, V., Santacaterina, A., Scolaro, T., Serafini, F., Spigone, B., Tolento, G., Vidali, C., Vitucci, P., and Zini, G.

Subjects
Hypofractionated Radiotherapy, medicine.medical_specialty, medicine.medical_treatment, Breast Neoplasms, Breast cancer radiotherapy, Nationwide survey, Hypofractionated radiotherapy, 030218 nuclear medicine & medical imaging, AIRO, Breast cancer, Partial-breast irradiation, Radiotherapy and neoadjuvant therapy, Re-irradiation, Survey, 03 medical and health sciences, 0302 clinical medicine, Surveys and Questionnaires, medicine, Humans, Radiology, Nuclear Medicine and imaging, Practice Patterns, Physicians', Medical prescription, Societies, Medical, Clinical Oncology, business.industry, General surgery, Radiation Oncologists, General Medicine, medicine.disease, Clinical Practice, Radiation therapy, Italy, 030220 oncology & carcinogenesis, Female, business
Abstract

To investigate the present attitude of the Italian Radiation Oncologists in the management of breast cancer (BC) concerning hypofractionated radiotherapy (hRT), partial-breast irradiation (PBI), re-irradiation (rRT) and radiotherapy after neoadjuvant chemotherapy (post-NAC RT). A nationwide, 21-point questionnaire was distributed online via SurveyMonkey. Seventy-four Italian Radiotherapy Centers answered to the survey. In most cases, the responding centers treated more than 100 BC patients/year between January 2016 and December 2017. Almost half of responding centers (49%) treated patients with hRT, out of these, 95% as routine practice for early-stage BC. Dose prescriptions ranged between 39 and 45 Gy indicating a high use of moderate hRT. The chest wall and regional lymph nodes were irradiated with hRT by 13% and 15% of the responding centers, respectively. PBI was used by 60% of responders, with different techniques. Only 0.6% of participants perform rRT after BC recurrence. Finally, only 11% of the interviewed centers responded to their attitude toward post-NAC RT, which, however, was indicated in 97% of patients after breast-conserving surgery. This survey shows a fairly good use of hRT and a moderate practice of PBI in Italy. Some practices like hRT to the chest wall and regional lymph nodes as well as rRT need further verification. Likewise, the management of post-NAC RT is very heterogeneous. Future national clinical collaborative studies are advocated in order to investigate these controversial topics about breast cancer radiotherapy.

Published
2020

26. PH-0492 Modesty in breast cancer patients during radiotherapy: interim results of a multicentric study

Author

Boldrini, L., primary, Elia, C., additional, Pollutri, V., additional, Dinapoli, L., additional, Caliandro, M., additional, Manfrida, S., additional, Masiello, V., additional, Chieffo, D., additional, Balducci, M., additional, Marazzi, F., additional, Gregucci, F., additional, Gambacorta, M.A., additional, Colangione, S.P., additional, Fiorentino, A., additional, and Valentini, V., additional

Published
2021
Full Text
View/download PDF

34. PO-1947: ARIA 15 Visual care Path for quality assurance of radiation oncology course

Author

Fragnoli, F., primary, Bonaparte, I., additional, Branà, L., additional, Aga, A., additional, De Masi, M., additional, Ciocia, A., additional, Indellicati, C., additional, Parabita, R., additional, Sanfrancesco, G., additional, De Pascali, C., additional, Berloco, F., additional, Caliandro, M., additional, Gregucci, F., additional, Surgo, A., additional, Carbonara, R., additional, and Fiorentino, A., additional

Published
2020
Full Text
View/download PDF

40. EP-1204 Quantitative signal intensity kinetics of normal tissues of the head and neck on the MR-Linac.

Author

Gregucci, F., primary, Bahig, H., additional, Mohamed, A.S., additional, He, R., additional, Elgohary, B.A., additional, Lee, H., additional, Ding, Y., additional, Wang, J., additional, Elhalawani, H., additional, Ibbott, G.S., additional, Chetvertkov, M., additional, Bosco, G., additional, Ikner, S., additional, Ng, S.P., additional, and Fuller, D.C., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results